Latest Period
Q2 2026
Security Snapshot
Atara Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (ATRA) Institutional Ownership
CUSIP: 046513206
13F Institutional Holders and Ownership History from Q2 2024 to Q2 2026
Institutions Reporting
35
Shares (Excl. Options)
4,467,954
Price
$11.48
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- ATRA on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 4,467,954
- Total 13F value
- $51,291,410
- Portfolio coverage rank
- 0%
- Share change
- +1,903,736
- Value change
- +$21,860,677
- Number of holders
- 35
- Shares outstanding
- 9,048,921
- SEC-reported price per share
- $9.23
- Insider filing price
- $9.23
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ATRA - Atara Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 046513206.
- 35 institutions reported positions in Q2 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 32 to 35 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $12,126,238 to $51,291,410.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 35 institutions filings for Q2 2026.
Security key
046513206
Latest holder period
Q2 2026
13F holders
35
13D/G owners
4
CIK / CUSIP context first
Open Q2 2026 holders
ATRA full holder history
Atara Biotherapeutics, Inc. SEC filings
Atara Biotherapeutics, Inc. company facts
Atara Biotherapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 046513206:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
ATRA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Panacea Innovation Ltd | 16% | +66% | $6,449,392 | +$3,759,892 | 1,318,894 | +140% | Panacea Innovation Limited | 07 May 2026 |
| Redmile Group, LLC | 9.9% | 0% | $10,926,921 | +$2,295,369 | 950,994 | +27% | Redmile Group, LLC | 22 Jul 2026 |
| EcoR1 Capital, LLC | 9.9% | $10,258,030 | 715,853 | EcoR1 Capital, LLC | 30 Sep 2025 | |||
| Point72 Asset Management, L.P. | 7.6% | $6,712,128 | 687,718 | Point72 Asset Management, L.P. | 30 Jun 2026 |
As of 30 Jun 2026, 35 institutional investors reported holding 4,467,954 shares of Atara Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (ATRA). This represents 49% of the company’s total 9,048,921 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
49%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 17% | 1,552,000 | +1458% | 0.88% | $17,816,960 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 9.4% | 850,000 | +21% | 0.01% | $9,758,000 |
| Point72 Asset Management, L.P. | 7.6% | 687,718 | +254% | 0.01% | $7,895,003 |
| Redmile Group, LLC | 4.9% | 441,701 | 0% | 0.34% | $5,070,727 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.7% | 247,047 | +13% | 0% | $2,836,100 |
| MACKENZIE FINANCIAL CORP | 2.6% | 233,249 | -26% | 0% | $2,677,699 |
| BlackRock, Inc. | 0.93% | 84,455 | +6.9% | 0% | $969,544 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.83% | 75,128 | +14% | 0% | $862,924 |
| STALEY CAPITAL ADVISERS INC | 0.55% | 50,000 | 0% | 0.02% | $574,000 |
| VANGUARD FIDUCIARY TRUST CO | 0.48% | 43,036 | +28% | 0% | $494,053 |
| ACADIAN ASSET MANAGEMENT LLC | 0.43% | 38,845 | -70% | 0% | $444,000 |
| JANE STREET GROUP, LLC | 0.34% | 30,345 | -10% | 0% | $348,360 |
| STATE STREET CORP | 0.29% | 26,453 | 0% | 0% | $303,680 |
| NORTHERN TRUST CORP | 0.18% | 16,591 | +34% | 0% | $190,465 |
| FMR LLC | 0.18% | 16,238 | 0% | 0% | $186,412 |
| XTX Topco Ltd | 0.17% | 15,303 | 0% | $175,678 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.15% | 14,000 | -57% | 0% | $160,720 |
| MILLENNIUM MANAGEMENT LLC | 0.14% | 12,680 | -73% | 0% | $145,566 |
| CITADEL ADVISORS LLC | 0.11% | 10,159 | 0% | $116,625 | |
| MORGAN STANLEY | 0.1% | 9,178 | +0.1% | 0% | $105,368 |
| ROYAL BANK OF CANADA | 0.05% | 4,743 | +9.8% | 0% | $55,000 |
| UBS Group AG | 0.04% | 3,979 | -92% | 0% | $45,679 |
| Vanguard Global Advisers, LLC | 0.02% | 1,456 | 0% | 0% | $16,715 |
| SBI Securities Co., Ltd. | 0.02% | 1,404 | -11% | 0% | $16,118 |
| JONES FINANCIAL COMPANIES LLLP | 0.01% | 803 | +14% | 0% | $8,440 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
9
Latest
Q2 2026
Rows shown
1-9 of 9
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 4,467,954 | $51,291,410 | +$21,860,677 | $11.48 | 35 |
| 2026 Q1 | 2,564,230 | $12,126,238 | -$2,698,914 | $4.73 | 32 |
| 2025 Q4 | 2,049,655 | $37,062,796 | +$3,113,209 | $18.09 | 40 |
| 2025 Q3 | 1,883,136 | $26,983,314 | +$1,944,887 | $14.33 | 36 |
| 2025 Q2 | 1,803,350 | $13,921,685 | -$1,938,164 | $7.72 | 32 |
| 2025 Q1 | 2,086,793 | $12,393,904 | -$4,023,428 | $5.94 | 36 |
| 2024 Q4 | 2,368,286 | $31,519,295 | -$410,987 | $13.31 | 41 |
| 2024 Q3 | 2,414,500 | $19,628,975 | -$1,762,796 | $8.13 | 33 |
| 2024 Q2 | 2,653,675 | $22,554,322 | +$22,225,788 | $8.50 | 43 |